Macrophagic activation syndrome as a complication of systemic juvenile idiopathic arthritis: A case report

Main Article Content

Ornella Ruiz
Carlos Gallón
Tatiana González

Keywords

Macrophage activation syndrome, inflammation, arthritis juvenile.

Abstract

Background: Macrophagic activation syndrome (MAS) may appear as a complication in patients with rheumatic diseases, it has been more frequently associated with the systemic form of juvenile idiopathic arthritis and systemic lupus erythematosus.
Case report: We present the case of a school-aged patient, who debuted with MAS as a complication of juvenile systemic idiopathic arthritis, refractory to conventional treatments and with an adequate response to biological therapy.
Discussion: MAS is a life-threatening autoinflammatory disorder, characterized by the activation of the intracellular inflamosoma with proliferation of T lymphocytes and the mononuclear phagocytic system, and hyperproduction of inflammatory prostaglandins such as IL 1, IL 6 and IL 18; its diagnosis is based on a combination of clinical signs and biochemical and histological abnormalities.

Abstract 166 | PDF (Español (España)) Downloads 203 HTML (Español (España)) Downloads 22 XML Downloads 0

References

Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM. 2002. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 27;132(29-30):414-422. PubMed PMID: 12428187. Epub 2002/11/13. eng.

Athreya BH. 2002. Is macrophage activation syndrome a new entity? Clin Exp Rheumatology. Mar-Apr;20(2):121-123. PubMed PMID: 12051388. Epub 2002/06/08. eng.

Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. 2006. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr. 148(5):683- 686. PubMed PMID: 16737887. Epub 2006/06/02. eng.

Behrens EM, Beukelman T, Paessler M, Cron RQ. 2007. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 34(5):1133- 1138. PubMed PMID: 17343315. Epub 2007/03/09. eng.

Coca A, Bundy KW, Marston B, Huggins J, Looney RJ. 2009. Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin. Clinical immunology (Orlando, Fla).132(1):10-18. PubMed PMID: 19297252. Epub 2009/03/20. eng. DOI 10.1016/j.clim.2009.02.005

Cuende E, Vesga JC, Perez LB, Ardanaz MT, Guinea J. 2001. Macrophage activation syndrome as the initial manifestation of systemic onset juvenile idiopathic arthritis. Clin Exp Rheumatol. 19(6):764-765. PubMed PMID: 11791663. Epub 2002/01/17. eng.

Deane S, Selmi C, Teuber SS, Gershwin ME. 2010. Macrophage activation syndrome in autoimmune disease. Int Arch Allergy Immunol. 153(2):109-120. PubMed PMID: 20407267. Epub 2010/04/22. eng DOI 10.1159/000312628

Emmenegger U, Frey U, Reimers A, Fux C, Semela D, Cottagnoud P, Spaeth PJ, Neftel KA. 2001. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol. 68(1):4-10. PubMed PMID: 11559930. Epub 2001/09/18. eng.

Grom AA, Passo M. 1996. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 129(5):630-632. PubMed PMID: 8917224. Epub 1996/11/01. eng. DOI 10.1002/art.23734

Gupta A, Tyrrell P, Valani R, Benseler S, Weitzman S, Abdelhaleem M. 2008. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. Sep;51(3):402-404. PubMed PMID: 18523990. Epub 2008/06/05. eng. DOI 10.1002/pbc.21564

Hadchouel M, Prieur AM, Griscelli C. 1985. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 106(4):561-566. PubMed PMID: 3981309. Epub 1985/04/01. eng.

Hone N, Donnelly C, Houk JB, Mina R. 2017. Macrophage Activation Syndrome in Scleroderma. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. J Clin Rheumatol. 23(2):120-121. PubMed PMID: 28225516. Epub 2017/02/23. eng. DOI 10.1097/RHU.0000000000000512

Hone N, Donnelly C, Houk JB, Mina R. 2017. Macrophage Activation Syndrome in Scleroderma. Mar;23(2):120-121. DOI 10.1097/RHU.0000000000000512

Janka GE. 1983. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr. 140(3):221-230. PubMed PMID: 6354720. Epub 1983/06/01. eng.

Kumakura S. 2005. Hemophagocytic syndrome. Intern Med. Apr; 44(4):278-280. PubMed PMID: 15897634. Epub 2005/05/18. eng.

Latino GA, Manlhiot C, Yeung RS, Chahal N, McCrindle BW. 2010. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol. 32(7):527-531. PubMed PMID: 20485197. Epub 2010/05/21. eng. DOI 10.1097/MPH.0b013e3181dccbf4

Parodi A, Davi S, Pringe AB, Pistorio A, Ruperto N, Magni-Manzoni S, et al. 2009. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 60(11):3388-3399. PubMed PMID: 19877067. Epub 2009/10/31. eng. DOI 10.1002/art.24883

Ravelli A, Davi S, Minoia F, Martini A, Cron RQ. 2015. Macrophage Activation Syndrome. Hematol Oncol Clin North Am. 29(5):927-941. PubMed PMID: 26461152. Epub 2015/10/16. eng. DOI 10.1016/j.hoc.2015.06.010

Ravelli A, Grom AA, Behrens EM, Cron RQ. 2012. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 13(4):289-298. PubMed PMID: 22418018. Epub 2012/03/16. eng. DOI 10.1038/gene.2012.3

Rossi-Semerano L, Hermeziu B, Fabre M, Kone-Paut I. 2011. Macrophage activation syndrome revealing familial Mediterranean fever. Arthritis Care Res (Hoboken). 63(5):780-783. PubMed PMID: 21557533. Epub 2011/05/11. eng. DOI 1002/acr.20418

Schulert GS & Grom AA. 2014. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 28(2):277-292. PubMed PMID: 24974063. Pubmed Central PMCID: PMC4074772. Epub 2014/06/30. eng. DOI 10.1016/j.berh.2014.03.002

Schulert GS & Grom AA. 2015. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 66:145-159. PubMed PMID: 25386930. Epub 2014/11/12. eng. DOI 10.1146/annurev-med-061813-012806

Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. 2001. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford). Nov;40(11):1285-92. PubMed PMID: 11709613. Epub 2001/11/16. eng.

Usmani GN, Woda BA, Newburger PE. 2013. Advances in understanding the pathogenesis of HLH. Br J Haematol. 161(5):609-622. PubMed PMID: 23577835. Epub 2013/04/13. eng.

Wallace CA & Sherry DD. 1997. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis and Rheum. 40(10):1852-1855. PubMed PMID: 9336421. Epub 1997/10/23. eng